Cellectar Biosciences to Host Conference Call with Texas Oncology Hematologist M. Yair Levy, M.D. on January 19, 2024 to Discuss Iopofosine I 131 Pivotal Topline Results Jan 12, 2024
Cellectar Biosciences Partners with MiBA, a Data Subsidiary of American Oncology Network, to Advance the Treatment of Waldenstrom's Macroglobulinemia in the Community Setting Jan 11, 2024
Cellectar Biosciences Announces Positive Topline Data Achieving Primary Endpoint in Pivotal Clinical Study of Iopofosine I 131 in Waldenstrom’s Macroglobulinemia Jan 8, 2024
Cellectar Biosciences Expands Iopofosine I 131 Collaboration with Wisconsin Alumni Research Foundation Dec 19, 2023
Cellectar to Release Top-line Data from WM Pivotal Trial During the JP Morgan Healthcare Conference the Week of January 8, 2024 Nov 2, 2023
Cellectar Biosciences Partners with Florida Cancer Specialists & Research Institute to Support the Treatment of Waldenstrom's Macroglobulinemia in the Community Setting Oct 25, 2023
Cellectar Biosciences to Announce Third Quarter Earnings Results and Host a Conference Call on Thursday, November 2, 2023 Oct 24, 2023